Abstract
Introduction
Tobacco use is the leading cause of preventable disease and death in the United States. Cigarette smoking accounts for more than 480,000 premature deaths annually and costs the United States approximately $130 billion in direct medical expenses and $150 billion in lost productivity each year (1) . Despite progress over the past several decades, declines in adult cigarette smoking have slowed in recent years (2, 3) . In 2012, current cigarette smoking among US adults was 18.1%, or nearly 42.1 million people (4) . Moreover, the use of nontraditional tobacco products, including little cigars and electronic cigarettes, has become prevalent (5, 6) .
Health professionals play an important role in educating their patients about the health risks of tobacco use and in providing effective cessation interventions. Most smokers want to quit, health professionals have frequent contact and high credibility with smokers, and brief clinical interventions are effective in motivating and assisting tobacco users to quit (7) . The 2008 update to the US Public Health Service Clinical Practice Guideline for Treating Tobacco Use and Dependence recommends that clinicians and health care delivery systems consistently identify and document tobacco use status and treat every tobacco user seen in a health care setting (7) . Specifically, the guideline recommends the "5A" model to help patients quit using tobacco. The approach encourages health professionals to ask patients if they use tobacco, advise them to quit, assess their willingness to quit, assist them by providing or referring for counseling or additional treatment and by offering medication (unless contraindicated), and to arrange for follow-up contact to prevent relapse (7) . However, effective screening and treatment of tobacco use are not consistently administered in clinical settings (7) . Therefore, enhanced populationbased and clinical efforts are warranted to prevent and reduce tobacco use in this setting (7, 8) .
The Healthy People 2020 objectives for health systems change call for increasing tobacco screening in hospital ambulatory care settings to 66.2% (TU-9.2) and increasing tobacco cessation counseling in hospital ambulatory care settings to 24.9% (TU-10.2) (9). The National Quality Forum has also endorsed specific clinical quality measures on tobacco use assessment and cessation interventions (10) .
Studies have assessed the extent of tobacco use screening and cessation assistance in physician outpatient settings (11) (12) (13) ; however, little is known about these practices in hospital outpatient settings, which account for approximately 1 in 10 outpatient visits. To address this gap, we analyzed aggregated data on hospital outpatient visits made by adults aged 18 years or older from the 2005-2010 National Hospital Ambulatory Medical Care Survey (NHAMCS) to determine the prevalence, correlates, and trends in screening for tobacco use and tobacco cessation assistance in the United States.
Methods
We analyzed data from the 2005-2010 NHAMCS, the most recent aggregated public use data set available during this article preparation. The NHAMCS is a national probability sample of visits to the emergency and outpatient departments of noninstitutional general and short-stay hospitals (excluding federal, military, and Veterans Administration hospitals) in the 50 US states and the District of Columbia.
The basic sampling unit for NHAMCS is the patient visit or encounter, which is systematically selected over a randomly assigned 4-week reporting period. Although NHAMCS captures both emergency department (ED) and hospital outpatient visits, tobacco use status is captured only during hospital outpatient visits (ED visits do not include any information on patients' tobacco use). As a result, the scope of our analyses was limited to hospital outpatient visits only. (14) .
Tobacco use was defined as smoking cigarettes or cigars, using snuff, or chewing tobacco. The status of a patient not currently using tobacco was marked "not current." The status of a patient currently using tobacco was marked "current." If it could not be determined whether the patient currently used or did not use tobacco, that patient's status was marked "unknown." Tobacco use screening during hospital outpatient visits was defined as documentation of screening for either current tobacco use or no current use on the patient record form (PRF). Tobacco cessation assistance was defined as documentation of either tobacco counseling or cessation medications during visits by persons aged 18 years or older who were current tobacco users. Tobacco counseling was defined as information given in the form of health education to the patient on topics related to tobacco use and exposure to secondhand smoke, information on smoking cessation and prevention of tobacco use, and referrals to other health professionals for smoking cessation programs. Provision of medications was identified through patient charts as medications that were ordered, supplied, administered, or continued. Data on medications were entered as free text for each visit, and medications were limited to no more than 8 prescription or over-the-counter tobacco cessation medications, which included nicotine replacement therapy (nicotine patch, gum, lozenge, nasal spray, or inhaler), bupropion, or varenicline. The hospital staff and census field representatives were responsible for completing PRFs for data abstraction.
Tobacco use screening and cessation assistance during visits were assessed by age (18-24 y, 25-44 y, 45-64 y, ≥65 y), sex, race/ethnicity (non-Hispanic white; non-Hispanic black; Hispanic; other race/multiple race, non-Hispanic), poverty level (percentage of people living at or below the federal level in a patient's zip code), health insurance type (private insurance; Medicare, Medicaid or State Children's Health Insurance Program [SCHIP] ; no insurance; other), and tobacco use status (current tobacco user, nonuser). Assessed visit-and clinic-related characteristics included whether the physician/provider was the patient's primary care physician (yes, no), major reason for visit (new problem <3-month onset; chronic problem; presurgery/postsurgery; preventive care), clinic type (general medicine, surgery, obstetrics and gynecology, substance abuse, other), and hospital electronic medical record use (yes, no).
Analyses were conducted using SAS version 9.2 (SAS Institute, Inc) and SUDAAN version 10.0.2 (RTI International) and restricted to records in which current tobacco use status was recorded. Data were adjusted for nonresponse and weighted to be nationally representative; 95% confidence intervals were calculated and estimates were considered significant if confidence intervals did not overlap. The overlapping confidence interval approach is not a formal statistical test for assessing differences; formal statistical testing may have resulted in different conclusions. Multivariate logistic regression with orthogonal polynomials was used to analyze linear trends from 2005 through 2010, adjusted for sex, age, and race/ethnicity (α = .05). Tobacco use screening during hospital outpatient visits varied by patient's race/ethnicity; visits made by Hispanics (55.4%) were less likely to receive tobacco use screening than those by non-Hispanic whites (65.1%). Patients who visited their primary care physician or provider were more likely to receive tobacco use screening (71.6%) than those who visited a physician who was not their primary care physician or provider (58.5%). Patients who made visits for a chronic problem (routine or flare-up) were less likely to receive tobacco use screening (59.9%) than those who visited with a new problem (<3 months onset) (67.9%). Patients who made visits to general medicine clinics (67.1%) were more likely to receive tobacco use screening than those who made visits to surgical clinics (55.7%) or clinics with other specialties (45.2%), excluding obstetrics and gynecology (62.8%) and substance abuse clinics (68.3%). Screening for tobacco use did not vary by poverty level. 
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Among patients who screened positive for current tobacco use, 24.5% (or an estimated 17.1 million visits) received any cessation assistance, including tobacco counseling, a prescription or order for a cessation medication at the visit, or both. Cessation assistance was higher for visits made by those with Medicaid/SCHIP PREVENTING CHRONIC DISEASE VOLUME 12, E132 PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY
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Discussion
We found that tobacco use screening occurred during most US adult visits to a hospital outpatient department from 2005 through 2010 (63.0%); however, screening did not occur in more than 1 in 3 visits. Moreover, among patients who were identified as current tobacco users, only 24.5% received any tobacco cessation assistance, including counseling, medications, or both. Consistent with the Public Health Service Clinical Practice Guideline, it is essential that clinicians and the health-care delivery systems consistently identify and document tobacco use status and treat every tobacco user with cessation counseling and US Food and Drug Administration (FDA)-approved tobacco cessation medications, except when medically contraindicated or with specific populations for which evidence of effectiveness of medications is insufficient, such as pregnant women, smokeless tobacco users, light smokers, and adolescents (7).
Disparities in tobacco use screening were observed across population groups. For example, tobacco use screening was lower among Hispanic patients than among non-Hispanic whites, a finding that is similar to a study of outpatient visits to office-based physicians from 2001 through 2005; in that study, lack of insurance or more new-patient visits did not explain this ethnic difference (15) . The lower prevalence of tobacco use screening among Hispanic patients may be attributable to cultural and language differences between patients and physicians, which have previously been identified as barriers to cancer screening (16) . To address these barriers to preventive services for Hispanic patients as well as other underrepresented patient populations, medical school curricula could include training programs for medical students in assisting patients whose primary language is not English (17, 18) . Although screening for tobacco use did not vary by poverty level, visits made by patients living in high poverty areas had higher rates of documented current tobacco use. This finding is consistent with population-based studies that document higher smoking prevalence among adults living below the federal poverty level (19) . Furthermore, prevalence of current tobacco use was higher among visits made to substance abuse clinics than those made to other types of clinics, which is consistent with findings from existing research (20) . Targeted efforts to enhance tobacco use screening and the provision of effective cessation treatments to people with substance use disorders can help reduce tobacco use and tobacco-related illness and death among this vulnerable population (8) . Similarly, current tobacco use was lower for preventive care visits, which could be attributed to greater time being devoted to tobacco use screening and counseling during preventive care visits than nonpreventive care visits or to people with unhealthy lifestyles being less likely to seek preventive care.
Patients visiting their primary care physician or provider had a higher prevalence of receiving tobacco use screening and cessation counseling than patients who visited a physician who was not their primary care physician, perhaps because the primary care physicians were providing more routine care than specialized care, and tobacco cessation counseling may have been provided as part of a wellness or preventive care visit. Outpatient visits made by PREVENTING CHRONIC DISEASE VOLUME 12, E132 PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY
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patients with a chronic problem were less likely to receive tobacco use screening than visits with a new problem (<3-month onset). This finding could be because patients having chronic conditions may experience more emphasis on receiving treatment by their physicians for their illness than on prevention (eg, tobacco use screening). From 2005 through 2010, hospital outpatient visits with no documented insurance or visits with Medicaid/SCHIP insurance had a higher prevalence of current tobacco use than those insured by private insurance or Medicare. However, neither private insurers nor state Medicaid programs consistently provide comprehensive coverage of evidence-based cessation treatments (8) . For example, in 2014, although all 51 Medicaid programs covered some form of tobacco-dependence treatment for some Medicaid enrollees, only 7 states covered all 7 FDA-approved cessation medications and individual and group counseling for all Medicaid enrollees (21) . Therefore, more efforts are warranted to meet the Healthy People 2020 objective (TU-8) of increasing comprehensive Medicaid insurance coverage of evidence-based cessation treatments for nicotine dependency (9) .
Ongoing changes in the US health care system offer opportunities to improve the use of clinical preventive services among adults. In particular, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (referred to as the Affordable Care Act), and other national initiatives offer increasing tobacco use cessation treatment coverage (22) . Effective January 2014, the Affordable Care Act prohibited traditional state Medicaid programs that cover prescription medications from excluding FDA-approved cessation medications, including over-the-counter medications, from Medicaid drug coverage. As of July 2011, Medicaid began allowing states to apply for 50% administrative match funds for telephone quitline services provided to Medicaid enrollees. Also as a part of the Affordable Care Act, as of January 2014, Medicaid expansion alternative benefit plans and newly qualified health insurance plans operating in the Health Insurance Marketplace are required to offer their members cessation coverage without cost sharing (23) . The requirement to provide cessation coverage without cost sharing also applies to all private health plans, except for those that have continuously maintained "grandfathered" status since March 23, 2010 (24) . The Marketplace allows eligible people and small businesses with up to 50 employees to purchase health insurance coverage from plans that meet criteria outlined in the Affordable Care Act. The federal government has established a Marketplace for states that have not yet created their own.
Several barriers can impede clinician assessment of and treatment for tobacco users, including lack of time, lack of knowledge of effective intervention strategies, inadequate payment for treatment, and lack of institutional support for routine assessment and treatment of tobacco use (3). Health care systems can support physician interventions by instituting effective systems-level changes that make screening for tobacco use and brief cessation interventions for tobacco users a standard part of every office visit. Provider-reminder systems can increase health care providers' assessment and treatment of tobacco use in a range of clinical settings and populations. Provider reminder systems remind or prompt providers to screen and advise patients on tobacco use and cessation, and can be implemented as chart stickers, vital sign stamps, medical record flow sheets, check lists, or as part of electronic medical records (8, 25 ).
This study is subject to at least 6 limitations. First, the definition of tobacco counseling included any information on tobacco use or secondhand smoke exposure, as well as referrals to tobacco cessation programs. Therefore, we could not assess the type of information provided or track the use of the 5A's more precisely (3) . Second, because bupropion can be prescribed as an antidepressant as well as for tobacco cessation, it is unclear which of these indications this medication was prescribed for. Third, tobacco counseling was only available for the current visit; therefore, it was not possible to determine the extent of health education during previous visits. Fourth, the study did not assess all types of tobacco use, including use of emerging products such as electronic cigarettes. Fifth, NHAMCS data were for 2005 through 2010; therefore, the estimates of tobacco use screening and cessation assistance may have changed. Finally, tobacco use screening may not have occurred at all visits by patients who had multiple visits to a sampled physician; thus, some visits with tobacco use screening or cessation assistance may have been missed.
Our study findings indicate that more than one-third (37.0%) of hospital outpatient visits, or 26.7 million annually, had no documentation of tobacco use status. Moreover, cessation assistance was not provided during 3 of 4 visits, or approximately 8.8 million annually. These findings underscore the need for enhanced efforts to encourage clinicians and the health care delivery systems to consistently identify and document tobacco use status and to treat every tobacco user with cessation counseling. The Centers for Disease Control and Prevention (CDC) recommends that states implement policies and other effective community-based strategies that increase tobacco cessation, in addition to working with health care systems, insurers, and purchasers of health insurance, to expand coverage for tobacco cessation and implement health system changes that support these effective clinical interventions (8, 25) . Other proven population-based interventions for increasing cessation include increasing the unit price of tobacco products, hard-hitting mass media campaigns, and comprehensive smoke-free policies in worksites and public places (8, 25) . Implementation of these proven policies and interventions, in concert with efforts to PREVENTING CHRONIC DISEASE 
